Investor's Business Daily on MSN
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts
Regeneron stock jumped on Tuesday after the biotech company reported adjusted earnings of $11.83 per share on $3.75 billion ...
REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...
Zacks Investment Research on MSN
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Regeneron (REGN) came out with quarterly earnings of $11.83 per share, beating the Zacks Consensus Estimate of $9.44 per share. This compares to earnings of $12.46 per share a year ago. These figures ...
Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the ...
Investing.com - Regeneron Pharma (NASDAQ: REGN) reported third quarter EPS of $11.83, $2.19 better than the analyst estimate of $9.64. Revenue for the quarter came in at $3.75B versus the consensus ...
Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and ...
Dupixent shows stable positive dynamics and becomes the main asset, while sales of Eylea are under pressure. Regeneron still has a strong pipeline, but the focus is shifting toward oncology. Valuation ...
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
StockStory.org on MSN
Regeneron Earnings: What To Look For From REGN
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you ...
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback